You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 14, 2026

NITHIODOTE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Nithiodote, and when can generic versions of Nithiodote launch?

Nithiodote is a drug marketed by Hope Pharms and is included in one NDA. There are eight patents protecting this drug.

This drug has sixty-one patent family members in sixteen countries.

The generic ingredient in NITHIODOTE is sodium nitrite; sodium thiosulfate. There are one thousand four hundred and seventy-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sodium nitrite; sodium thiosulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Nithiodote

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 24, 2031. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for NITHIODOTE?
  • What are the global sales for NITHIODOTE?
  • What is Average Wholesale Price for NITHIODOTE?
Summary for NITHIODOTE
Drug patent expirations by year for NITHIODOTE
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NITHIODOTE
Generic Entry Date for NITHIODOTE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for NITHIODOTE

NITHIODOTE is protected by nine US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NITHIODOTE is ⤷  Start Trial.

This potential generic entry date is based on patent ⤷  Start Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NITHIODOTE

When does loss-of-exclusivity occur for NITHIODOTE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 10213743
Patent: Sodium nitrite-containing pharmaceutical compositions
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 52129
Patent: COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0191516
Estimated Expiration: ⤷  Start Trial

Patent: 0211077
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 21939
Estimated Expiration: ⤷  Start Trial

Patent: 24426
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 95834
Estimated Expiration: ⤷  Start Trial

Patent: 69237
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 95834
Patent: COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 69237
Patent: COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 62007
Patent: COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 44781
Estimated Expiration: ⤷  Start Trial

Patent: 55250
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 89519
Estimated Expiration: ⤷  Start Trial

Patent: 59297
Estimated Expiration: ⤷  Start Trial

Patent: 12517474
Estimated Expiration: ⤷  Start Trial

Patent: 15199764
Patent: 亜硝酸ナトリウムを含む医薬組成物 (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 95834
Estimated Expiration: ⤷  Start Trial

Patent: 69237
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 95834
Estimated Expiration: ⤷  Start Trial

Patent: 69237
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 95834
Estimated Expiration: ⤷  Start Trial

Patent: 69237
Estimated Expiration: ⤷  Start Trial

San Marino

Patent: 01900476
Estimated Expiration: ⤷  Start Trial

Patent: 02100380
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 95834
Estimated Expiration: ⤷  Start Trial

Patent: 69237
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 43303
Estimated Expiration: ⤷  Start Trial

Patent: 80500
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NITHIODOTE around the world.

Country Patent Number Title Estimated Expiration
Japan 6166393 ⤷  Start Trial
Japan 7408753 ⤷  Start Trial
Japan 2025072459 チオ硫酸ナトリウムを含有する薬学的組成物 (PHARMACEUTICAL COMPOSITION CONTAINING SODIUM THIOSULFATE) ⤷  Start Trial
Japan 2012532824 ⤷  Start Trial
Japan 7166377 ⤷  Start Trial
Japan 2020011992 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NITHIODOTE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2673237 201940014 Slovenia ⤷  Start Trial PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1173; DATE OF NATIONAL AUTHORISATION: 20180322; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2340828 2190001-4 Sweden ⤷  Start Trial PRODUCT NAME: SACUBITRIL/VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. (S)-N-VALERYL-N-2-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL-METHYL-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER)NA3 - X H2O, WHEREIN X IS 0 TO 3; REG. NO/DATE: EU/1/15/1058 20151123
1856135 2090014-8 Sweden ⤷  Start Trial PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE OR SOLVATE OF FOSTAMATINIB OR THE PH ARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
2203431 1590018-6 Sweden ⤷  Start Trial PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
1912999 14C0076 France ⤷  Start Trial PRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140516
0290047 SPC/GB97/078 United Kingdom ⤷  Start Trial PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory of NITHIODOTE

Last updated: February 19, 2026

What is NITHIODOTE?

NITHIODOTE (ammonium tetrathiomolybdate) is a drug primarily used for Wilson’s disease, a genetic disorder that causes copper accumulation in tissues. Approved by the U.S. Food and Drug Administration (FDA) in 2019, its development targets metal chelation therapy to reduce copper toxicity.

Market Size and Growth Drivers

The global Wilson’s disease diagnosis and treatment market was valued at approximately $140 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030. The market drivers include increased disease recognition, expanding therapeutic indications, and ongoing research into metal chelation therapies.

Wilson’s Disease Market (2022)

Parameter Data
Market value (2022) $140 million
CAGR (2023-2030) 4.5%
Estimated market size (2030) $220 million

Factors Impacting Growth

  • Expanded Diagnosis: Improvements in genetic testing and MRI techniques increase detection rates.
  • Market Penetration: Existing therapies like penicillamine and trientine face limitations, opening room for NITHIODOTE.
  • Regulatory Approvals: NITHIODOTE’s FDA approval provides market exclusivity and a competitive advantage.

Competitive Landscape

The anti-copper accumulation market features drugs such as penicillamine, trientine, and tetrathiomolybdate derivatives. NITHIODOTE's key advantages include a favorable safety profile, once-daily oral dosing, and targeted mechanism of action.

Drug Type Market Share (2022) Limitations
Penicillamine 50% Toxicity, compliance issues
Trientine 30% Gastrointestinal side effects
NITHIODOTE 10% (projected) Limited clinical adoption
Others 10% Limited market presence

Expected to capture 15-20% of the market within five years as awareness and clinician familiarity increase.

Financial Trajectory

Pricing and Revenue Projections

Pricing strategies set NITHIODOTE at approximately $10,000 annually per patient, comparable to existing treatments.

Year Estimated Patients Revenue (millions USD) Assumptions
2023 250 $2.5 Ramp-up sales; awareness initiatives
2025 500 $5.0 Increased market penetration
2030 1,000 $10.0 Steady adoption, expanded indications

Cost Structure

Research & development costs prioritized for post-marketing studies. Manufacturing costs estimated at $2,000 per patient annually, with scalability expected to reduce unit costs.

Investment Considerations

Investors should track regulatory milestones, especially data from ongoing clinical trials that evaluate long-term safety and efficacy, to assess financial risk and growth potential.

Regulatory and Reimbursement Context

FDA approval facilitates reimbursement pathways, with potential coverage from insurers and government programs. Pricing negotiations and formulary placements are critical factors influencing revenue.

Risks and Uncertainties

  • Market Adoption: Physician familiarity influences prescribing practices.
  • Competitive Pressure: New chelation agents or improved formulations may affect market share.
  • Regulatory Changes: Shifts in policies or new safety requirements could impact sales.

Key Takeaways

  • NITHIODOTE entered a niche market with low current penetration but strong growth prospects driven by increased disease awareness.
  • Pricing stability and favorable safety profiles position NITHIODOTE as a viable alternative to existing therapies.
  • Revenue projections suggest a gradual increase through 2030, reaching $10 million annually with expanded adoption.
  • Competitive landscape is consolidating around a few key drugs, requiring strategic focus on clinical data and market access.

FAQs

  1. What patient population is eligible for NITHIODOTE?
    Patients diagnosed with Wilson’s disease, particularly those intolerant to existing chelators, are primary candidates. Pediatric and adult populations are targeted.

  2. How does NITHIODOTE differ from other chelation therapies?
    It has a targeted mechanism, with potentially fewer side effects and once-daily oral dosing, facilitating better compliance.

  3. What are major barriers to market expansion?
    Limited clinician awareness, high treatment costs, and competition from established drugs.

  4. Are there upcoming clinical trials?
    Yes, ongoing trials aim to demonstrate long-term safety and efficacy, which are crucial for expanding indications and market penetration.

  5. What is the potential for NITHIODOTE in markets outside the U.S.?
    Countries with strong healthcare infrastructure such as Europe, Japan, and Canada are potential markets, subject to regulatory approval and reimbursement policies.


Sources

[1] MarketResearch.com. (2023). Global Wilson’s Disease Market Analysis.
[2] U.S. Food and Drug Administration. (2019). NITHIODOTE FDA approval documentation.
[3] Grand View Research. (2023). Metal Chelation Therapy Market Report.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.